智通财经APP获悉，1月27日晚间，若羽臣(003010.SZ)发布2025年年度业绩预告。公告显示，公司预计 2025年实现归属于上市公司股东的净利润1.76亿元至2亿元，同比增长66.61%至89.33%；基本每股收益 预计为0.57元至0.64元，公司盈利能力呈现稳步提升态势。 内部管理方面，2025年，若羽臣持续推进精细化运营战略，从供应链管理、市场营销，运营管理等多个 维度着手，深挖成本优化空间。通过对费用和预算的严格把控，以及对业务流程的持续优化，公司有效 降低了运营成本，提升了资源利用效率，整体经营效益得到了大幅提升。 品牌管理业务方面，与多品牌的深度合作，进一步巩固了若羽臣在全链路、全渠道数字化服务领域的领 先地位，实现业绩高增。 自有品牌业务方面，绽家在保持多款单品在细分领域的领先优势基础上推出战略单品香氛洗衣液，上市 后实现销售爆发；斐萃在产品端、渠道端持续发力，推动收入高速增长。 若羽臣在自有品牌及品牌管理业务上的持续发力，以及内部管理的优化，使得公司2025年年度业绩预期 向好，展现了其在新消费品牌领域的综合实力与成长韧性。 ...

Core Viewpoint - The company, Ruoyuchen, anticipates a significant increase in net profit for the year 2025, projecting a growth of 66.61% to 89.33% compared to the previous year, indicating a strong upward trend in profitability [1] Group 1: Financial Performance - The expected net profit for 2025 is projected to be between 176 million to 200 million yuan, with a basic earnings per share forecasted at 0.57 to 0.64 yuan, reflecting a steady improvement in profitability [1] Group 2: Business Development - In the proprietary brand segment, the company has launched a strategic product, a scented laundry detergent, which has seen explosive sales following its introduction, while the brand Feicui continues to drive rapid revenue growth through product and channel enhancements [1] Group 3: Brand Management - The company has strengthened its leading position in the digital service sector through deep collaborations with multiple brands, resulting in significant performance growth [1] Group 4: Internal Management - For 2025, the company is committed to a refined operational strategy focusing on supply chain management, marketing, and operational management to optimize costs. By strictly controlling expenses and budgets, as well as continuously improving business processes, the company has effectively reduced operational costs and enhanced resource utilization efficiency [1] Group 5: Overall Outlook - The ongoing efforts in proprietary brand and brand management, along with optimized internal management, have led to a positive outlook for the company's 2025 annual performance, showcasing its comprehensive strength and resilience in the new consumer brand sector [1]

Group 1 - The internet e-commerce sector increased by 0.73% on January 27, with Kai Chun Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] - Key stocks in the internet e-commerce sector showed significant price movements, with Kai Chun Co., Ltd. rising by 11.40% to a closing price of 37.13 [1] Group 2 - The net inflow of main funds in the internet e-commerce sector was 181 million yuan, while retail investors experienced a net outflow of 301 million yuan [2] - The stock "Xin Xun Da" saw a decline of 4.84%, closing at 21.06 yuan, with a trading volume of 161,500 shares [2] - The stock "Hua Kai Yi Bai" had a net inflow of 65.46 million yuan from main funds, indicating strong institutional interest despite overall sector outflows [3]

每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 每经AI快讯，若羽臣1月27日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润17600万 ~20000万元，比上年同期增长66.61%~89.33%，基本每股收益0.57元~0.64元。业绩变动主要原因是，自 有品牌业务收入高速增长，绽家在保持多款单品在细分领域的领先优势基础上推出战略单品香氛洗衣 液，上市后实现销售爆发；斐萃在产品端、渠道端持续发力，推动收入高速增长；品牌管理业务实现业 绩高增，与多品牌深度合作，进一步巩固了公司在全链路、全渠道数字化服务领域的领先地位；在内部 管理方面，2025年，公司持续推进精细化运营战略，从供应链管理、市场营销，运营管理等多个维度着 手，深挖成本优化空间。 （记者 曾健辉） 每日经济新闻 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 ...

若羽臣公告，预计2025年度净利润为1.76亿元到2亿元，同比增长66.61%到89.33%。预计扣除非经常性 损益后的净利润为1.7亿元到1.94亿元，同比增长60.25%到82.87%。预计基本每股收益为0.57元/股到0.64 元/股。预计业绩增长主要得益于自有品牌业务收入高速增长，品牌管理业务实现业绩高增，以及公司 持续推进精细化运营战略，有效降低了运营成本，提升了资源利用效率。 ...

证券代码：003010 证券简称：若羽臣 公告编号：2026-002 广州若羽臣科技股份有限公司 2025 年年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为正值且属于同向上升 50%以上情形 （1）以区间数进行业绩预告的 | 项 目 | 本报告期 | | | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 归属于上市公司 | | 17,600 | ～ | 20,000 | 10,563.62 | | 股东的净利润 | 比上年同期增长 | 66.61% | ～ | 89.33% | | | 扣除非经常性损 | | 17,000 | ～ | 19,400 | 10,608.45 | | 益后的净利润 | 比上年同期增长 | 60.25% | ～ | 82.87% | | | 基本每股收益 （元/股） | | 0.57 | ～ | 0.64 | 0.38 | 1、自 ...

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, indicating strong performance compared to the market [2]. Core Insights - The cosmetics and medical beauty sector has outperformed the market recently, with the Shenwan Beauty Care Index rising by 2.0% from January 16 to January 23, 2026, surpassing the Shenwan A Index by 0.8 percentage points [4][5]. - December 2025 saw a significant increase in social retail sales for cosmetics, reaching 38 billion yuan, with a growth rate of 8.8%, indicating robust demand even in the off-season. The overall growth rate for Q4 was 9.9%, significantly higher than the annual growth of 5.1% for 2025, driven by promotional events like Double 11 [10][17]. - The report anticipates continued high consumer demand in Q1 2026, supported by new product launches and regulatory approvals in the medical beauty sector [10]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown strong performance, with the Shenwan Cosmetics Index increasing by 2.6% and the Shenwan Personal Care Index rising by 4.2%, both outperforming the Shenwan A Index [4][5]. Key Company Reviews - Lin Qingxuan (2657HK) is highlighted as a benchmark in the high-end domestic skincare market, with revenue projected to grow from 690 million yuan in 2022 to 1.21 billion yuan in 2024, representing a CAGR of 32.7%. The company is expected to turn a profit of 187 million yuan in 2024, a 120% increase year-on-year [11][12]. - Langzi Co., Ltd. (002612.SZ) forecasts a net profit of 900 million to 1.05 billion yuan for 2025, reflecting a year-on-year growth of 245.25% to 302.80% [4]. - Qingsong Co., Ltd. (300132.SZ) anticipates a net profit of 130 million to 165 million yuan for 2025, with a growth rate of 137.73% to 201.74% [4]. Market Trends - The report notes that the high-end skincare market is expanding, with the market size expected to reach 218.5 billion yuan by 2029. The concept of "oil-based skincare" is becoming mainstream, driving growth in the facial oil segment, which is projected to grow at a CAGR of 42.8% from 2019 to 2024 [12][14]. - E-commerce channels are increasingly important, with Lin Qingxuan achieving a 65.4% online revenue share in H1 2025, leveraging platforms like Douyin and Tmall for growth [13]. Sales Data - In December 2025, the total retail sales of cosmetics reached 38 billion yuan, with a year-on-year growth of 8.8%. The overall retail sales for cosmetics in 2025 were 465.3 billion yuan, reflecting a 5.1% increase [17][21].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 28.00 [1]. Core Insights - The company is expected to see a significant acceleration in performance in Q4, driven by high demand and improved capacity utilization. The projected revenue for 2025 is RMB 1.38 billion, representing a year-on-year increase of 19.75%, with net profit expected to reach RMB 370 million, up 48.9% [5][6]. - The company is well-positioned to benefit from the growing demand for functional sugars, with new production capacity expected to come online in 2026, further enhancing revenue growth [7][8]. Financial Projections - Revenue projections for the upcoming years are as follows: - 2024: RMB 1.15 billion (+32.64%) - 2025: RMB 1.38 billion (+19.74%) - 2026: RMB 1.74 billion (+25.99%) - 2027: RMB 2.23 billion (+28.52%) [4]. - Net profit forecasts are: - 2024: RMB 246 million (+27.26%) - 2025: RMB 367 million (+49.45%) - 2026: RMB 471 million (+28.27%) - 2027: RMB 620 million (+31.70%) [4]. - The company’s EPS is projected to increase from RMB 0.58 in 2024 to RMB 1.48 in 2027 [4]. Valuation Metrics - The company’s PE ratio is expected to decrease from 38.44 in 2024 to 15.23 in 2027, indicating improving valuation as earnings grow [4]. - The PB ratio is projected to decline from 5.62 in 2024 to 3.37 in 2027, reflecting a more attractive valuation over time [4]. - The EV/EBITDA ratio is expected to fall from 24.75 in 2024 to 9.79 in 2027, suggesting enhanced operational efficiency and profitability [4].

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 003010 | 若羽臣 | 37.52 | -1.86% | 4.37万 | 1.64亿 | | 301110 | 青木科技 | 76.09 | -1.81% | 4.84万 | 3.69亿 | | 605136 | 丽人丽妆 | 12.13 | -0.25% | 14.20万 | 1.73亿 | | 603613 | 国联股份 | 29.08 | -0.10% | 0 11.19万 | 3.26亿 | | 002315 | 焦点科技 | 53.00 | 0.13% | 9.04万 | 4.83亿 | | 600539 | 师头股份 | 11.23 | 0.27% | 11.03万 | 1.24亿 | | 600365 | ST通葡 | 3.20 | 0.63% | 2.60万 | 828.67万 | | 301558 | 三态股份 | 8.97 | 0.67% | 17.20万 | 1.55亿 | | 002640 | 跨境通 | 4.20 | ...

Core Insights - The nutrition and health sector is experiencing a surge in IPO activity, with many companies targeting the Hong Kong stock market for their listings [3][8] - The trend is driven by a combination of expansion needs and financial pressures faced by companies, prompting them to seek capital through public offerings [3][9] Group 1: IPO Activity - Since the beginning of 2025, at least 13 companies in the nutrition and health sector have either successfully listed or initiated the IPO process, with over 70% aiming for the Hong Kong market [3][8] - Notable companies include Newman, Xinqian Group, and Hengmei Health, with various business focuses such as maternal and infant products and functional food additives [1] Group 2: Reasons for Listing - Companies like Hengmei Health and Yujian Health are planning to use raised funds for significant production expansions, indicating a clear demand for growth [3] - Financial pressures, such as high current liabilities and asset-liability ratios exceeding 90%, are motivating companies like Yuwang Bio to pursue IPOs as a means to optimize capital structure [3][9] Group 3: A+H Listing Trend - Four out of the 13 companies are pursuing an A+H share listing model, reflecting a strategic goal for global expansion [5] - Brands leveraging new e-commerce channels, such as Xizi Health and Ruoyuchen, are also rapidly moving towards capital market engagement [5] Group 4: Hong Kong Market Appeal - The Hong Kong stock market has become increasingly attractive due to a systematic revaluation of Chinese assets and heightened interest from international long-term investors [8] - In 2025, the Hong Kong IPO market saw 114 new listings, a 63% increase year-on-year, with total fundraising reaching HKD 286.3 billion, a 227% increase [8] Group 5: Policy Support - The introduction of the "Science and Technology Enterprise Special Line" by the Hong Kong Stock Exchange has provided a more efficient pathway for companies to list, enhancing the appeal of the market [9] - Listing in Hong Kong offers companies not just financing opportunities but also helps in establishing international governance structures and enhancing global influence [9][10] Group 6: Strategic Implications - The trend towards listing in Hong Kong signifies a broader shift towards internationalization and standardization for domestic nutrition and health companies [10] - Companies are expected to improve financial transparency and information disclosure quality as they engage with global investors [10]